PhRMA Challenges Medicare's GLOBE Drug-Pricing Initiative

The Pharmaceutical Research and Manufacturers of America (PhRMA) has taken legal action against the U.S. government, challenging a new Medicare drug-pricing initiative known as the GLOBE model.

PhRMA's lawsuit, filed on October 7, 2026, contests the authority of the Centers for Medicare & Medicaid Services (CMS) in implementing the Global Benchmark for Efficient Drug Pricing without congressional approval. According to PhRMA, the model's approach of benchmarking U.S. drug prices against those in 19 other countries exceeds CMS's regulatory powers. The case, Pharmaceutical Research and Manufacturers of America v. Kennedy, is being reviewed in the U.S. District Court for the District of Columbia.

The GLOBE Model and Its Implications

Finalized by CMS in September, the GLOBE model aims to reduce costs for drugs under Medicare Part B by imposing higher rebates if U.S. prices surpass international benchmarks. This initiative focuses on medications given in clinical settings, such as cancer and autoimmune therapies, and is expected to cut out-of-pocket costs for eligible Medicare beneficiaries starting April 2027. The model will initially impact select geographic areas covering about 25% of Original Medicare participants.

Despite the model's potential to ease financial burdens on patients, PhRMA President Stephen J. Ubl expressed concerns that aligning with international prices could deter pharmaceutical innovation. Ubl emphasized the need to balance cost control with the encouragement of new drug development.

Regulatory and Legal Challenges

PhRMA's legal argument questions whether the GLOBE model is justified under the regulatory authorities established by Congress, specifically the Affordable Care Act. Their lawsuit seeks to overturn the rule based on the Administrative Procedure Act, suggesting that CMS has overstepped its bounds in executing a policy that should require legislative backing.

Historical context shows similar initiatives during the Trump administration encountered legal setbacks. Federal courts previously blocked plans to align Medicare prices with international rates due to procedural shortcomings. The ongoing case could set important precedents regarding the powers of federal agencies over healthcare pricing.

Potential Impact on Medicare and Manufacturers

The CMS estimates that the GLOBE model could cut Medicare Part B spending by about $440 million over its operational span. However, the model's scope excludes certain categories, like drugs for rare diseases and specific biologics, reducing the number of impacted manufacturers. Some pharmaceutical companies have also engaged in voluntary agreements with CMS, further narrowing the model's reach.

What Industry Professionals Should Watch

The court's forthcoming decision on the GLOBE model will significantly influence Medicare Part B's future cost management strategies. Insurance agents, carriers, and underwriters should closely monitor the case outcome, as legislative and regulatory shifts could reshape drug pricing frameworks and impact various stakeholders, including pharmaceutical companies and healthcare providers.

Keeping abreast of these developments will be crucial for compliance teams, claims professionals, and agency operations to adapt to any changes in regulatory requirements that might emerge from this legal battle.